112 / 119
111
Diretrizes AMB
moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J
Dermatol. 2010 Jan;162(1):137-46. PubMed PMID: 19903183.
30. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S,
Dooley LT, Gordon KB; PHOENIX 1 study investigators. Efficacy and
safety of ustekinumab, a human interleukin-12/23 monoclonal antibody,
in patients with psoriasis: 76-week results from a randomised, double-
blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May
17;371(9625):1665-74. PubMed PMID: 18486739.